3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
8
Thoracic
7
Dermatologic
7
Genitourinary
5
Head & Neck
2
Sarcoma
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Lymphoma
340
Lymphoma, Non-Hodgkin
295
Precursor Cell Lymphoblastic Leukemia-Lymphoma
249
Leukemia, Lymphocytic, Chronic, B-Cell
235
Lymphoma, Large B-Cell, Diffuse
217
Leukemia
186
Lymphoma, Follicular
183
Lymphoma, Mantle-Cell
167
Recurrence
142
Hodgkin Disease
141
Lymphoma, B-Cell
139
Leukemia, Myeloid, Acute
133
Burkitt Lymphoma
120
Lymphoma, B-Cell, Marginal Zone
94
Multiple Myeloma
86
Myelodysplastic Syndromes
83
Waldenstrom Macroglobulinemia
62
Lymphoma, T-Cell, Peripheral
57
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
52
Neoplasms
52
Lymphoma, T-Cell, Cutaneous
52
Hematologic Neoplasms
49
Lymphoma, Large-Cell, Anaplastic
43
Lymphoma, T-Cell
41
Lymphoma, Large-Cell, Immunoblastic
41
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
40
Mycosis Fungoides
38
Leukemia, B-Cell
34
Sezary Syndrome
30
Myeloproliferative Disorders
29
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Lymphoid
×
Clear all
NCT03598608
2026-02-05
MK-4280-003
Merck Sharp & Dohme LLC
Phase 1/2
Completed
137 enrolled